{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:57:45Z","timestamp":1777532265166,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ritonavir\u2010boosted darunavir (DRV\/r) is a preferred protease inhibitor in pregnant women living with HIV. Current practice at British Columbia's referral centre (the Oak Tree Clinic) is to dose DRV\/r as 800\/100\u2009mg daily throughout pregnancy, although some guidelines recommend DRV\/r 600\/100\u2009mg twice daily due to altered pharmacokinetics with once\u2010daily dosing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We describe the effect of once\u2010daily DRV\/r on viral suppression, vertical transmission, adverse drug effects and adherence in pregnant women living with HIV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective analysis of pregnant women living with HIV in British Columbia. Eligible women gave birth between January 2015 and August 2021, and took DRV\/r 800\/100\u2009mg daily at any time during pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010four women were included in this study. The mean (SD) age was 33 (5)\u2009years. Thirty (88%) women were diagnosed with HIV prior to pregnancy, with 22 (73%) having viral suppression at baseline. Four (12%) were diagnosed in pregnancy, with a median baseline viral load of 9616 copies\/mL (range 8370\u2013165\u2009000). Viral suppression was achieved by 16 (100%), 24 (75%) and 26 (74%) women in the first, second and third trimesters, respectively. No vertical transmission occurred. This combination was well tolerated, with adverse drug effects that did not result in discontinuation or change in therapy. Most women maintained &gt;75% adherence to once\u2010daily DRV\/r at all times during pregnancy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ritonavir\u2010boosted darunavir 800\/100\u2009mg daily appears to be an appropriate dosing strategy for pregnant women living with HIV who are able to maintain optimal adherence.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13546","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T02:52:49Z","timestamp":1696992769000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Daily ritonavir\u2010boosted darunavir for viral suppression in pregnancy (<scp>DRV\u2010P<\/scp>)"],"prefix":"10.1111","volume":"25","author":[{"given":"Nikolina","family":"Gacic","sequence":"first","affiliation":[{"name":"Children's and Women's Health Centre of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Tulloch","sequence":"additional","affiliation":[{"name":"Children's and Women's Health Centre of British Columbia  Vancouver British Columbia Canada"},{"name":"Oak Tree Clinic BC Women's Hospital  Vancouver British Columbia Canada"},{"name":"Women's Health Research Institute BC Women's Hospital  Vancouver British Columbia Canada"},{"name":"Faculty of Pharmaceutical Sciences University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Money","sequence":"additional","affiliation":[{"name":"Children's and Women's Health Centre of British Columbia  Vancouver British Columbia Canada"},{"name":"Oak Tree Clinic BC Women's Hospital  Vancouver British Columbia Canada"},{"name":"Women's Health Research Institute BC Women's Hospital  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Tkachuk","sequence":"additional","affiliation":[{"name":"Children's and Women's Health Centre of British Columbia  Vancouver British Columbia Canada"},{"name":"Oak Tree Clinic BC Women's Hospital  Vancouver British Columbia Canada"},{"name":"Faculty of Pharmaceutical Sciences University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"The Epidemiology of HIV in Canada [Internet]","author":"Challacombe L","year":"2021"},{"key":"e_1_2_8_3_1","volume-title":"People living with HIV in Canada: infographic [Internet]","year":"2020"},{"key":"e_1_2_8_4_1","volume-title":"2019 Surveillance Highlights [Internet]","year":"2021"},{"key":"e_1_2_8_5_1","volume-title":"Population\u2010specific HIV\/AIDS Status Report","year":"2012"},{"key":"e_1_2_8_6_1","volume-title":"British Columbia Guidelines for the Care of HIV Positive Pregnant Women and Interventions to Reduce Perinatal Transmission [Internet]","author":"Money D","year":"2013"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328350995c"},{"key":"e_1_2_8_8_1","volume-title":"Table 7. Situation\u2010Specific Recommendations for Use of Antiretroviral Drugs in Pregnant People and Nonpregnant People Who Are Trying to Conceive [Internet].","year":"2023"},{"key":"e_1_2_8_9_1","volume-title":"Table 14. Antiretroviral Drug Use in Pregnant People with HIV: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy [Internet]","year":"2023"},{"key":"e_1_2_8_10_1","volume-title":"Darunavir (Prezista\u00ae) [Internet]","author":"HIVclinic.ca","year":"2021"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku400"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12366"},{"key":"e_1_2_8_13_1","first-page":"22","volume-title":"Abstracts of the 14th International Workshop on Clinical Pharmacology of HIV Therapy. Vol 3. Reviews in Antiviral Therapy & Infectious Diseases","author":"Curran A","year":"2013"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19485"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3291"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky567"},{"key":"e_1_2_8_17_1","volume-title":"British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update) [internet]","author":"Gilleece Y","year":"2021"},{"key":"e_1_2_8_18_1","volume-title":"Treatment of Pregnant Women Living with HIV or Women Considering Pregnancy [Internet]","author":"EACS","year":"2022"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000668"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12047"},{"key":"e_1_2_8_21_1","volume-title":"Antiretroviral (ARV) Treatment of Adult HIV Infection [Internet]","author":"BCCFE","year":"2020"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20180016"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.17.199802"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013016"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.12.052"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T08:26:10Z","timestamp":1705479970000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/hiv.13546"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13546","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"2023-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}